# PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program
Canonical URL: https://biopharmsignal.com/news/PEPG/pepgen-announces-presentations-at-the-15th-international-myotonic-dystrophy-consortium-highlighting-clinical-data-from-the-pgn-edodm1-program
Ticker: PEPG
Company: PepGen
Source: PepGen
Published: 2026-06-25 13:46 EST
Original Source URL: https://investors.pepgen.com
## Summary

BOSTON --(BUSINESS WIRE)--May 21, 2026-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its

## Article Body
BOSTON --(BUSINESS WIRE)--May 21, 2026-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its
## Recent Company News
- 2026-06-25 13:46 EST — [PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program](https://biopharmsignal.com/news/PEPG/pepgen-announces-presentations-at-the-15th-international-myotonic-dystrophy-consortium-highlighting-clinical-data-from-the-pgn-edodm1-program) — Source: PepGen
- 2026-06-25 13:46 EST — [PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights](https://biopharmsignal.com/news/PEPG/pepgen-reports-first-quarter-2026-financial-results-and-recent-corporate-highlights) — Source: PepGen
- 2026-06-25 13:46 EST — [PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society](https://biopharmsignal.com/news/PEPG/pepgen-announces-oral-presentations-at-the-30th-annual-international-congress-of-the-world-muscle-society) — Source: PepGen
- 2026-06-25 13:46 EST — [PepGen to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/PEPG/pepgen-to-participate-in-upcoming-investor-conferences) — Source: PepGen
- 2026-06-25 13:46 EST — [PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights](https://biopharmsignal.com/news/PEPG/pepgen-reports-third-quarter-2025-financial-results-and-recent-corporate-highlights) — Source: PepGen
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)